|
1. Schurawitzki HR, Stiglbauer W, Graninger C, Herold D, Polzleitner OC, Burghuber D, et al. Interstitial lung disease inprogressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1960; 176: 755–9. 2. Bianchi FA, Bistue AR, Wendt VE, Puro HE, Keech MK. Analysis of twenty-seven cases of progressive systemic sclerosis (including two with combined systemic lupus erythematosus) and a review of the literature. J Chronic Dis 1996; 19: 953–77. 3. Varga J. Systemic sclerosis and related disorder. In: Longo DL, Kaspar DL, Jamson Jl, Fauci AS, Loscalzo J. Harrison's principle of internal medicine. Mc Graw Hill; 2012. P. 2757-70. 4. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011; 2011. 5. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin Thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140-6. 6. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138(3): 540–6. 7. Barnes TC, Spiller DG, Anderson ME, Edwards SW, Moots RJ. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis?. Ann Rheum Dis 2011; 70(2): 366-72. 8. Ludici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmun Rev 2015; 14(7): 575-8. 9. Jurisic Z, Martinovic-Kaliterna D, Marasovic-Krstulovic D, Perkovic D, Tandara L, Salamunic I, et al. Relationship between interleukin 6 and cardiac involvement in systemic sclerosis. Rheumatology (Oxford) 2013; 52(7): 1298-302. 10. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40: 435–46. 11. Schmidt K, Martinez-Gamboa L, Meier S, Witt CH, Meisel CH, Hanitsch LG, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11(4): R111. 12. Shima Y. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Modern Rheumatol 2019; 29(2): 294-301. 13. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J,Yamamura K, et al. Generation of plasmacytomas with thechromosomal translocation t(12;15) in interleukin 6 transgenicmice. Proc Natl Acad Sci USA 1992; 89(1): 232–5. 14. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H.Interferon beta 2/B-cell stimulatory factor type 2 shares identitywith monocyte-derived hepatocyte-stimulating factor and regulatesthe major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84(20): 7251–5. 15. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, MatsudaT, et al. Interleukin-6 triggers the association of its receptor witha possible signal transducer, gp130. Cell 1989; 58(3): 573–81. 16. Minami M, Inoue M, Wei S, Takeda K, Matsumoto M, Kishimoto T, et al. STAT3 activation is a critical step in gp130- mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci USA 1996; 93(9): 3963–6. 17. Denton CP, Ong VH. Interleukin-6 and related proteins as biomarkers in Systemic sclerosis. J Scleroderma Relat Disord 2017; 2(2): 13-19. 18. Mel_endez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56(2): 225–31. 19. Yousif M, Habib R, Esaely H, Yasin R, Sonbol A. Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement. Egyptian J Chest Dis Tuberculosis 2015; 64(1): 237-41. 20. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin- 2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35(1): 67–72. 21. Giacomelli R, Cipriani P, Danese C, Pizzuto F, Lattanzio R, Parzanese I, et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. J Rheumatol 1996; 23(2): 291–6. 22. Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994; 73(6): 493. 23. Rojas M, Rodríguez Y, Monsalve DM, Pacheco y, Acosta-Ampudia, Rodríguez-Jimenez YM, et al. Cytokine imbalance in patients with systemic sclerosis and resilience: the key role of interleukin-6. Clin Exp Rheumatol 2019; 37(119): 15-22. 24. Cardoneanu A, Burlui AM, Macovei LA, Bratoiu I, Richter P, Rezus E. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?. Biomedicines 2022; 10: 318. 25. Kawaguchi Y, Contribution of interleukin-6 to the pathogenesis of systemic sclerosis. Scleroderma Relat Disord 2017; 2(2): 6-12. 26. Abo-alella DA, Mostafa DI, Shahaw AA. Association of Serum IL 6 with Different Clinical Presentations of Systemic Sclerosis Patients: A Case-Control Study. Zagazig Univ Med J 2021; 27(2). 27. Crestani B1, Seta N, De Bandt M, Soler P, Rolland C, Dehoux M, et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994; 149(5): 1260-5 28. Nishioka K, Katayama H, Kondo H, Shinkai H, Ueki K, Tamaki K, et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc): Scleroderma Research Committee Japan. J Dermatol 1996; 23: 677–82. 29. Abdel-Magied RA, Kamel SR, Said AF, Ali HM, Abdel Gawad EA, Moussa M. Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement. Sarcoidosis Vasculitis Diffuse Lung Dis 2016; 33; 321-30. 30. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels asindicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30(2): 231–7.
|
_-_Copy.png)
.png){kind=logo}
